Multi-centre, Multi-national, Prospective, Randomised, Open-label, Comparison of Bivalirudin to Other Guideline Based Current Therapies (Excluding Bivalirudin)

Trial Profile

Multi-centre, Multi-national, Prospective, Randomised, Open-label, Comparison of Bivalirudin to Other Guideline Based Current Therapies (Excluding Bivalirudin)

Completed
Phase of Trial: Phase III

Latest Information Update: 15 May 2016

At a glance

  • Drugs Bivalirudin (Primary) ; Enoxaparin sodium; Glycoprotein inhibitors
  • Indications Acute coronary syndromes; Embolism and thrombosis; Myocardial infarction
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Acronyms EUROMAX
  • Sponsors The Medicines Company
  • Most Recent Events

    • 17 Oct 2015 Status changed from active, no longer recruiting to completed as reported by European Clinical Trials Database.
    • 02 Sep 2015 Results presented at the ESC Congress 2015: Annual Congress of the European Society of Cardiology
    • 24 Aug 2015 According to The Medicines Company media release, data from this study will be presented at the 2015 European Society of Cardiology (ESC) Congress.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top